Tuesday, November 1, 2022

The FDA last week approved

The FDA last week approved Coherus BioSciences, Inc.’s Lucentis biosimilar, Cimerli, across all five of its indications. The anti-VEGF therapy will be interchangeable with Lucentis, a blockbuster for manufacturer Roche, and hold interchangeability exclusivity for 12 months. The first Lucentis biosimilar, Byooviz, was approved in September 2021, but for just three of Lucentis’s indications, including wet age-related macular degeneration (AMD). For the treatment of AMD, Lucentis holds covered or better status for 86% of all insured lives under the medical benefit, to Byooviz’s 68%.

 


Cost-Control Efforts Pay Off for Cigna in Second Quarter

by Leslie Small

 

 

 

Top Stars Performers Credit Coordinated Messaging, Targeted Outreach

by Lauren Flynn Kelly

 

 

 


UnitedHealth 3Q Earnings Call: Execs Talk Redeterminations, Acquisitions, Inflation

 

 

 

 

 



As Expected, Top MA-PD Payers See Star Ratings Declines

Featured Infographic

 

 

 

 

NOTES: Analysis does not include enrollment data from contracts that were too new to be rated or did not have enough data available to measure a star rating. About 73,000 of Humana Inc.’s MA-PD members were enrolled in a contract rated 2.5 stars. Guidewell Mutual Holding Corp.’s enrollment includes its January 2022 acquisition of Triple-S Management Corp. It is also the parent company of Florida Blue and Capital Health Plan, Inc. Kaiser Permanente’s enrollment figures represent the sum of its seven regional managed care organizations.

SOURCES: CMS. DHP, AIS’s Directory of Health Plans, as of October 2022.

 


Centene Corp. last week said it selected...

Centene Corp. last week said it selected Cigna Corp.’s Express Scripts to serve as its pharmacy benefits manager, beginning in 2024. "Selecting our future PBM partner represents a major value creation plan milestone and positions us to capture significant value for our members, partners, and stakeholders in 2024 and beyond," CEO Sarah London said in the company’s third-quarter earnings release. Centene is transitioning away from its in-house PBM, Envolve, following multiple lawsuits alleging Centene overcharged state Medicaid programs for prescription drugs. Centene currently covers 17,144,851 members, with 68.6% enrolled in Medicaid.

 


PDP Star Ratings Dip Amid End of Pandemic-Era Adjustments

by Leslie Small